DNA damage response regulation by microRNAs as a therapeutic target in cancer

DNA Repair

Volumn 47, Issue , 2016, Pages 1-11

  Majidinia, Maryam ^a,b,c   Yousefi, Bahman ^b,c,d  

^a URMIA UNIVERSITY   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Chemotherapy; DNA damage response; DNA repair; microRNA

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 107; MICRORNA 125B; MICRORNA 138; MICRORNA 145; MICRORNA 146; MICRORNA 155; MICRORNA 181A; MICRORNA 181B; MICRORNA 182; MICRORNA 193A 3P; MICRORNA 203; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 25; MICRORNA 27A; MICRORNA 29B; MICRORNA 31; MICRORNA 32; MICRORNA 320; MICRORNA 34A; MICRORNA 451; MICRORNA 96; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DNA; PLATINUM DERIVATIVE; RNA; TAXOID; TUMOR PROTEIN;

BIOGENESIS; DNA DAMAGE RESPONSE; DNA REPAIR; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DNA DAMAGE; DRUG EFFECTS; GENETICS; GENOMIC INSTABILITY; HUMAN GENOME; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; MICRORNAS; NEOPLASM PROTEINS; NEOPLASMS; PLATINUM COMPOUNDS; RNA, NEOPLASM; TAXOIDS; TRANSCRIPTION, GENETIC;

EID: 84993940390     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2016.09.003     Document Type: Review

References (194)

1. [1] Pearl, L.H., Schierz, A.C., Ward, S.E., Al-Lazikani, B., Pearl, F.M., Therapeutic opportunities within the DNA damage response. Nat. Rev. Cancer 15:3 (2015), 166–180.
2. [2] Tian, H., Gao, Z., Li, H., Zhang, B., Wang, G., Zhang, Q., et al. DNA damage response–a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 358:1 (2015), 8–16.
3. [3] Brown, J.S., Jackson, S.P., Ubiquitylation, neddylation and the DNA damage response. Open Biol., 5(4), 2015, 150018.
4. [4] Karanika, S., Karantanos, T., Li, L., Corn, P.G., Thompson, T.C., DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 34:22 (2015), 2815–2822.
5. [5] Goldstein, M., Kastan, M.B., The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu. Rev. Med. 66 (2015), 129–143.
6. [6] O'Connor, M.J., Targeting the DNA damage response in cancer. Mol. Cell 60:4 (2015), 547–560.
7. [7] Howard, S.M., Yanez, D.A., Stark, J.M., DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining. PLoS Genet., 11(1), 2015, e1004943.
8. [8] Fokas, E., Prevo, R., Hammond, E.M., Brunner, T.B., McKenna, W.G., Muschel, R.J., Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat. Rev. 40:1 (2014), 109–117.
9. [9] Yousefi, B., Samadi, N., Ahmadi, Y., Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA Repair 22 (2014), 24–29.
10. [10] Wang, H., Zhang, X., Teng, L., Legerski, R.J., DNA damage checkpoint recovery and cancer development. Exp. Cell Res. 334:2 (2015), 350–358.
11. [11] Tessitore, A., Cicciarelli, G., Del Vecchio, F., Gaggiano, A., Verzella, D., Fischietti, M., et al. MicroRNAs in the DNA damage/repair network and cancer. Int. J. Genomics, 2014, 2014.
12. [12] Jiricny, J., The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 7:5 (2006), 335–346.
13. [13] Hoeijmakers, J.H., DNA damage, aging, and cancer. New Engl. J. Med. 361:15 (2009), 1475–1485.
14. [14] Caldecott, K.W., Single-strand break repair and genetic disease. Nat. Rev. Genet. 9:8 (2008), 619–631.
15. [15] San Filippo, J., Sung, P., Klein, H., Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem 77 (2008), 229–257.
16. [16] Ambros, V., microRNAs: tiny regulators with great potential. Cell 107:7 (2001), 823–826.
17. [17] Vasudevan, S., Tong, Y., Steitz, J.A., Switching from repression to activation: microRNAs can up-regulate translation. Science 318:5858 (2007), 1931–1934.
18. [18] Melton, C., Judson, R.L., Blelloch, R., Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 463:7281 (2010), 621–626.
19. [19] Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136:2 (2009), 215–233.
20. [20] Ameres, S.L., Zamore, P.D., Diversifying microRNA sequence and function. Nat. Rev. Mol. Cell Biol. 14:8 (2013), 475–488.
21. [21] Krol, J., Loedige, I., Filipowicz, W., The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11:9 (2010), 597–610.
22. [22] Rüegger, S., Großhans, H., MicroRNA turnover: when, how, and why. Trends Biochem. Sci. 37:10 (2012), 436–446.
23. [23] Westholm, J.O., Lai, E.C., Mirtrons: microRNA biogenesis via splicing. Biochimie 93:11 (2011), 1897–1904.
24. [24] Fabian, M.R., Sonenberg, N., The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat. Struct. Mol. Biol. 19:6 (2012), 586–593.
25. [25] Gregory, R.I., Chendrimada, T.P., Cooch, N., Shiekhattar, R., Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123:4 (2005), 631–640.
26. [26] Schwarz, D.S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., Zamore, P.D., Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:2 (2003), 199–208.
27. [27] Griffiths-Jones, S., The microRNA registry. Nucleic Acids Res. 32:Suppl. (1) (2004), D109–D111.
28. [28] Filipowicz, W., Bhattacharyya, S.N., Sonenberg, N., Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 9:2 (2008), 102–114.
29. [29] Jalali, S., Bhartiya, D., Lalwani, M.K., Sivasubbu, S., Scaria, V., Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS One, 8(2), 2013, e53823.
30. [30] Ouellet, D.L., Perron, M.P., Gobeil, L.-A., Plante, P., Provost, P., MicroRNAs in gene regulation: when the smallest governs it all. BioMed Res. Int., 2006, 2006.
31. [31] Friedman, R.C., Farh, K.K.-H., Burge, C.B., Bartel, D.P., Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:1 (2009), 92–105.
32. [32] Lewis, B.P., Burge, C.B., Bartel, D.P., Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:1 (2005), 15–20.
33. [33] Hutvágner, G., Zamore, P.D., A microRNA in a multiple-turnover RNAi enzyme complex. Science 297:5589 (2002), 2056–2060.
34. [34] Zeng, Y., Cullen, B.R., Sequence requirements for micro RNA processing and function in human cells. RNA 9:1 (2003), 112–123.
35. [35] Zeng, Y., Wagner, E.J., Cullen, B.R., Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell 9:6 (2002), 1327–1333.
36. [36] Doench, J.G., Petersen, C.P., Sharp PA: siRNAs can function as miRNAs. Genes. Dev. 17:4 (2003), 438–442.
37. [37] Seggerson, K., Tang, L., Moss, E.G., Two genetic circuits repress the Caenorhabditis elegans heterochronic gene lin-28 after translation initiation. Dev. Biol. 243:2 (2002), 215–225.
38. [38] Brennecke, J., Hipfner, D.R., Stark, A., Russell, R.B., Cohen, S.M., Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113:1 (2003), 25–36.
39. [39] Bottai, G., Pasculli, B., Calin, G.A., Santarpia, L., Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert Opin. Biol. Ther. 14:11 (2014), 1667–1683.
40. [40] Yousefi, B., Rahmati, M., Ahmadi, Y., The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life Sci. 99 (2014), 14–17.
41. [41] Sharma, V., Misteli, T., Non‐coding RNAs in DNA damage and repair. FEBS Lett. 587:13 (2013), 1832–1839.
42. [42] Cannell, I.G., Kong, Y.W., Johnston, S.J., Chen, M.L., Collins, H.M., Dobbyn, H.C., et al. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc. Natl. Acad. Sci. U. S. A. 107:12 (2010), 5375–5380.
43. [43] Georges, S.A., Biery, M.C., Kim S-y Schelter, J.M., Guo, J., Chang, A.N., et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res. 68:24 (2008), 10105–10112.
44. [44] Hl, Yan, Xue, G., Mei, Q., Yz, Wang, Fx, Ding, Liu, M.F., et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J. 28:18 (2009), 2719–2732.
45. [45] Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. ABBV Cell Cycle 6:13 (2007), 1586–1593.
46. [46] Ugalde, A.P., Ramsay, A.J., de la Rosa, J., Varela, I., Mariño, G., Cadiñanos, J., et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J. 30:11 (2011), 2219–2232.
47. [47] Chen, L., Zhang, R., Li, P., Liu, Y., Qin, K., Z-q, Fa, et al. P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2. Neurosci. Lett. 534 (2013), 327–332.
48. [48] Su, W., Hopkins, S., Nesser, N.K., Sopher, B., Silvestroni, A., Ammanuel, S., et al. The p53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf. J. Immunol. 192:1 (2014), 358–366.
49. [49] Pichiorri, F., Suh, S.-S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18:4 (2010), 367–381.
50. [50] Zhang, Y., Geng, L., Talmon, G., Wang, J., MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J. Biol. Chem. 290:10 (2015), 6215–6225.
51. [51] Aguda, B.D., Kim, Y., Piper-Hunter, M.G., Friedman, A., Marsh, C.B., MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc. Natl. Acad. Sci. U. S. A. 105:50 (2008), 19678–19683.
52. [52] He, S., Yang, S., Deng, G., Liu, M., Zhu, H., Zhang, W., et al. Aurora kinase A induces miR-17-92 cluster through regulation of E2F1 transcription factor. Cell. Mol. Life Sci. 67:12 (2010), 2069–2076.
53. [53] Krysan, K., Kusko, R., Grogan, T., O'Hearn, J., Reckamp, K.L., Walser, T.C., et al. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol. Cancer Res. 12:5 (2014), 765–774.
54. [54] Zhang, K., Dai, L., Zhang, B., Xu, X., Shi, J., Fu, L., et al. MiR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells. J. Cell. Physiol. 230:4 (2015), 903–910.
55. [55] Yang, C.-S., Rana, T.M., Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs. Mol. Biosyst. 9:1 (2013), 10–17.
56. [56] Su, X., Chakravarti, D., Cho, M.S., Liu, L., Gi, Y.J., Lin, Y.-L., et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467:7318 (2010), 986–990.
57. [57] Galardi, S., Mercatelli, N., Farace, M.G., Ciafre, S.A., NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 39:9 (2011), 3892–3902.
58. [58] Li, W., Guo, F., Wang, P., Hong, S., Zhang, C., miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Curr. Mol. Med. 14:1 (2014), 185–195.
59. [59] Niu, J., Shi, Y., Tan, G., Yang, C.H., Fan, M., Pfeffer, L.M., et al. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J. Biol. Chem. 287:26 (2012), 21783–21795.
60. [60] Niu, J., Xue, A., Chi, Y., Xue, J., Wang, W., Zhao, Z., et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene 35:10 (2016), 1302–1313.
61. [61] Wang, Y., Taniguchi, T., MicroRNAs and DNA damage response: implications for cancer therapy. ABBV Cell Cycle 12:1 (2013), 32–42.
62. [62] Fukuda, T., Yamagata, K., Fujiyama, S., Matsumoto, T., Koshida, I., Yoshimura, K., et al. DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat. Cell Biol. 9:5 (2007), 604–611.
63. [63] Gregory, R.I., Yan K-p Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 432:7014 (2004), 235–240.
64. [64] Junttila, M.R., Evan GI. p53—a Jack of all trades but master of none. Nat. Rev. Cancer 9:11 (2009), 821–829.
65. [65] Boominathan, L., The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev. 29:4 (2010), 613–639.
66. [66] Boominathan, L., The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One, 5(5), 2010, e10615.
67. [67] Krell, J., Stebbing, J., Frampton, A.E., Carissimi, C., Harding, V., De Giorgio, A., et al. The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA–mRNA interaction network. Lancet, 385, 2015, S15.
68. [68] Garibaldi, F., Falcone, E., Trisciuoglio, D., Colombo, T., Lisek, K., Walerych, D., et al. Mutant p53 inhibits miRNA biogenesis by interfering with the Microprocessor complex. Oncogene 35:29 (2016), 3760–3770.
69. [69] Zhang, X., Wan, G., Berger, F.G., He, X., Lu, X., The ATM kinase induces microRNA biogenesis in the DNA damage response. Mol. Cell 41:4 (2011), 371–383.
70. [70] Trabucchi, M., Briata, P., Garcia-Mayoral, M., Haase, A.D., Filipowicz, W., Ramos, A., et al. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 459:7249 (2009), 1010–1014.
71. [71] Chendrimada, T.P., Gregory, R.I., Kumaraswamy, E., Norman, J., Cooch, N., Nishikura, K., et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436:7051 (2005), 740–744.
72. [72] Dent, P., Yacoub, A., Fisher, P.B., Hagan, M.P., Grant, S., MAPK pathways in radiation responses. Oncogene 22:37 (2003), 5885–5896.
73. [73] Wang, X., Zhao, X., Gao, P., Wu, M., c-Myc modulates microRNA processing via the transcriptional regulation of Drosha. Sci. Rep., 3, 2013.
74. [74] Mao, G., Lee, S., Ortega, J., Gu, L., Li, G.-M., Modulation of microRNA processing by mismatch repair protein MutLα. Cell Res. 22:6 (2012), 973–985.
75. [75] Kawai, S., Amano, A., BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. J. Cell Biol. 197:2 (2012), 201–208.
76. [76] Tu, C.-C., Zhong, Y., Nguyen, L., Tsai, A., Sridevi, P., Tarn, W.Y., et al. The kinase ABL phosphorylates the microprocessor subunit DGCR8 to stimulate primary microRNA processing in response to DNA damage. Sci. Signal., 8(383), 2015, ra64.
77. [77] Lin, C.L., Wang, Y.-T., Yang, W.-Z., Hsiao, Y.-Y., Yuan, H.S., Crystal structure of human polynucleotide phosphorylase: insights into its domain function in RNA binding and degradation. Nucleic Acids Res., 2011 gkr1281.
78. [78] Suzuki, H.I., Arase, M., Matsuyama, H., Choi, Y.L., Ueno, T., Mano, H., et al. MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol. Cell 44:3 (2011), 424–436.
79. [79] Boele, J., Persson, H., Shin, J.W., Ishizu, Y., Newie, I.S., Søkilde, R., et al. PAPD5-mediated 3' adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease. Proc. Natl. Acad. Sci. U. S. A. 111:31 (2014), 11467–11472.
80. [80] Pothof, J., Verkaik, N.S., van IJcken, W., Wiemer, E.A., Ta, V.T., van der Horst, G.T., et al. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J. 28:14 (2009), 2090–2099.
81. [81] Liu, Y., Lu, X., Non-coding RNAs in DNA damage response. Am. J. Cancer. Res. 2:6 (2012), 658–675.
82. [82] Zhang, C., Peng, G., Non-coding RNAs: an emerging player in DNA damage response. Mutat. Res. Rev. Mutat. Res. 763 (2015), 202–211.
83. [83] Wang, Y., Huang, J.-W., Li, M., Cavenee, W.K., Mitchell, P.S., Zhou, X., et al. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol. Cancer Res. 9:8 (2011), 1100–1111.
84. [84] Lal, A., Pan, Y., Navarro, F., Dykxhoorn, D.M., Moreau, L., Meire, E., et al. miR-24–mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat. Struct. Mol. Biol. 16:5 (2009), 492–498.
85. [85] Yang, H., Luo, J., Liu, Z., Zhou, R., Luo, H., MicroRNA-138 regulates DNA damage response in small cell lung cancer cells by directly targeting H2AX. Cancer Invest. 33:4 (2015), 126–136.
86. [86] Valeri, N., Gasparini, P., Fabbri, M., Braconi, C., Veronese, A., Lovat, F., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. U. S. A. 107:15 (2010), 6982–6987.
87. [87] Valeri, N., Gasparini, P., Braconi, C., Paone, A., Lovat, F., Fabbri, M., et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl. Acad. Sci. U. S. A. 107:49 (2010), 21098–21103.
88. [88] Ng, W.L., Yan, D., Zhang, X., Mo, Y.-Y., Wang, Y., Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: m059J. DNA Repair 9:11 (2010), 1170–1175.
89. [89] Hu, H., Du, L., Nagabayashi, G., Seeger, R.C., Gatti, R.A., ATM is down-regulated by N-Myc–regulated microRNA-421. Proc. Natl. Acad. Sci. U. S. A. 107:4 (2010), 1506–1511.
90. [90] Yan, D., Ng, W.L., Zhang, X., Wang, P., Zhang, Z., Mo, Y.-Y., et al. Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One, 5(7), 2010, e11397.
91. [91] Liang, L., Zhu, J., Zaorsky, N.G., Deng, Y., Wu, X., Liu, Y., et al. MicroRNA-223 enhances radiation sensitivity of U87MG cells in vitro and in vivo by targeting ataxia telangiectasia mutated. Int. J. Radiat. Oncol. Biol. Phys. 88:4 (2014), 955–960.
92. [92] Zhang, X., Nie, Y., Li, X., Wu, G., Huang, Q., Cao, J., et al. MicroRNA-181a functions as an oncomir in gastric cancer by targeting the tumour suppressor gene ATM. Pathol. Oncol. Res. 20:2 (2014), 381–389.
93. [93] Guo, P., Lan, J., Ge, J., Nie, Q., Guo, L., Qiu, Y., et al. MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia–telangiectasia mutated. Exp. Cell Res. 320:2 (2014), 200–208.
94. [94] Di Francesco, A., De Pittà, C., Moret, F., Barbieri, V., Celotti, L., Mognato, M., The DNA-damage response to γ-radiation is affected by miR-27a in A549 cells. Int. J. Mol. Sci. 14:9 (2013), 17881–17896.
95. [95] van Balkom, B.W., De Jong, O.G., Smits, M., Brummelman, J., den Ouden, K., de Bree, P.M., et al. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood 121:19 (2013), 3997–4006.
96. [96] Wu, C.-W., Dong, Y.-J., Liang, Q.-Y., He, X.-Q., Ng, S.S., Chan, F.K., et al. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS One, 8(2), 2013, e57036.
97. [97] Song, L., Lin, C., Wu, Z., Gong, H., Zeng, Y., Wu, J., et al. miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase. PLoS One, 6(9), 2011, e25454.
98. [98] Wang, Y., Yu, Y., Tsuyada, A., Ren, X., Wu, X., Stubblefield, K., et al. Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 30:12 (2011), 1470–1480.
99. [99] Li, Y., Han, W., Ni, T.-T., Lu, L., Huang, M., Zhang, Y., et al. Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells. Oncol. Rep. 33:6 (2015), 2821–2828.
100. [100] Garcia, A.I., Buisson, M., Bertrand, P., Rimokh, R., Rouleau, E., Lopez, B.S., et al. Down‐regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol. Med. 3:5 (2011), 279–290.
101. [101] Hudson, R.S., Yi, M., Esposito, D., Watkins, S.K., Hurwitz, A.A., Yfantis, H.G., et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res., 2011 gkr1222.
102. [102] Mueller, A.C., Sun, D., Dutta, A., The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 32:9 (2013), 1164–1172.
103. [103] Moskwa, P., Buffa, F.M., Pan, Y., Panchakshari, R., Gottipati, P., Muschel, R.J., et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 41:2 (2011), 210–220.
104. [104] Sun, C., Li, N., Yang, Z., Zhou, B., He, Y., Weng, D., et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J. Natl. Cancer Inst. 105:22 (2013), 1750–1758.
105. [105] Song, L., Dai, T., Xie, Y., Wang, C., Lin, C., Wu, Z., et al. Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. J. Mol. Cell Biol. 4:2 (2012), 108–117.
106. [106] Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118:10 (2012), 2603–2614.
107. [107] Crosby, M.E., Kulshreshtha, R., Ivan, M., Glazer, P.M., MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 69:3 (2009), 1221–1229.
108. [108] Wang, Y., Huang, J.-W., Calses, P., Kemp, C.J., Taniguchi, T., MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res. 72:16 (2012), 4037–4046.
109. [109] Liu, R.-L., Dong, Y., Deng, Y.-Z., Wang, W.-J., Li, W.-D., Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. Tumor Biol. 36:7 (2015), 5011–5019.
110. [110] Maute, R.L., Schneider, C., Sumazin, P., Holmes, A., Califano, A., Basso, K., et al. tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 110:4 (2013), 1404–1409.
111. [111] Zhang, S., Deng, B., Zhang, Y., Jiang, N., Expression of miR-100 and RBSP3 in FTC-133 cells after exposure to 131I. Nucl. Med. Commun. 35:9 (2014), 932–938.
112. [112] Zhu, F., Liu, J.-L., Li, J.-P., Xiao, F., Zhang, Z.-X., Zhang, L., MicroRNA-124 (miR-124) regulates Ku70 expression and is correlated with neuronal death induced by ischemia/reperfusion. J. Mol. Neurosci. 52:1 (2014), 148–155.
113. [113] Martin, N.T., Nakamura, K., Davies, R., Nahas, S.A., Brown, C., Tunuguntla, R., et al. ATM–dependent miR-335 targets CtIP and modulates the DNA damage response. PLoS Genet., 9(5), 2013, e1003505.
114. [114] Zhang, S., Chen, H., Zhao, X., Cao, J., Tong, J., Lu, J., et al. REV3L 3' UTR 460 T > C polymorphism in microRNA target sites contributes to lung cancer susceptibility. Oncogene 32:2 (2013), 242–250.
115. [115] Tsai, Y.-S., Lin, C.-S., Chiang, S.-L., Lee, C.-H., Lee, K.-W., Ko Y-, C., Areca nut induces miR-23a and inhibits repair of DNA double-strand breaks by targeting FANCG. Toxicol. Sci., 2011 kfr182.
116. [116] Lee, J.-H., Park, S.-J., Jeong, S.-Y., Kim, M.-J., Jun, S., Lee, H.-S., et al. MicroRNA-22 suppresses DNA repair and promotes genomic instability through targeting of MDC1. Cancer Res. 75:7 (2015), 1298–1310.
117. [117] Le, M.T., Teh, C., Shyh-Chang, N., Xie, H., Zhou, B., Korzh, V., et al. MicroRNA-125b is a novel negative regulator of p53. Genes. Dev. 23:7 (2009), 862–876.
118. [118] Hu, W., Chan, C.S., Wu, R., Zhang, C., Sun, Y., Song, J.S., et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol. Cell 38:5 (2010), 689–699.
119. [119] Kumar, M., Lu, Z., Takwi, A.A.L., Chen, W., Callander, N.S., Ramos, K.S., et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 30:7 (2011), 843–853.
120. [120] Herrera-Merchan, A., Cerrato, C., Luengo, G., Dominguez, O., Piris, M.A., Serrano, M., et al. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. ABBV Cell Cycle 9:16 (2010), 3297–3305.
121. [121] Swarbrick, A., Woods, S.L., Shaw, A., Balakrishnan, A., Phua, Y., Nguyen, A., et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat. Med. 16:10 (2010), 1134–1140.
122. [122] Liu, Y., Xing, R., Zhang, X., Dong, W., Zhang, J., Yan, Z., et al. miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells. DNA Repair 12:9 (2013), 741–750.
123. [123] Xiao, J., Lin, H., Luo, X., Luo, X., Wang Z. miR-605 joins p53 network to form a p53: miR-605: Mdm2 positive feedback loop in response to stress. EMBO J. 30:3 (2011), 524–532.
124. [124] Rahman, M., Lovat, F., Romano, G., Calore, F., Acunzo, M., Bell, E.H., et al. miR-15b/16-2 regulates factors that promote p53 phosphorylation and augments the DNA damage response following radiation in the lung. J. Biol. Chem. 289:38 (2014), 26406–26416.
125. [125] Bouamar, H., Jiang, D., Wang, L., Lin, A.-P., Ortega, M., Aguiar, R.C., MicroRNA 155 control of p53 activity is context dependent and mediated by Aicda and Socs1. Mol. Cell. Biol. 35:8 (2015), 1329–1340.
126. [126] Ye, Z., Fang, J., Dai, S., Wang, Y., Fu, Z., Feng, W., et al. MicroRNA-34a induces a senescence-like change via the down-regulation of SIRT1 and up-regulation of p53 protein in human esophageal squamous cancer cells with a wild-type p53 gene background. Cancer Lett. 370:2 (2016), 216–221.
127. [127] Sarkar, S., Dey, B.K., Dutta, A., MiR-322/424 and-503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol. Biol. Cell 21:13 (2010), 2138–2149.
128. [128] Yang, X., Feng, M., Jiang, X., Wu, Z., Li, Z., Aau, M., et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb–E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes. Dev. 23:20 (2009), 2388–2393.
129. [129] Queiroz de Oliveira, P.E., Zhang, L., Wang, Z., Reese, C., Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21. ABBV Cell Cycle 8:19 (2009), 3157–3164.
130. [130] Pouliot, L.M., Chen, Y.-C., Bai, J., Guha, R., Martin, S.E., Gottesman, M.M., et al. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 72:22 (2012), 5945–5955.
131. [131] Mei, Z., Su, T., Ye, J., Yang, C., Zhang, S., Xie, C., The miR-15 family enhances the radiosensitivity of breast cancer cells by targeting G2 checkpoints. Radiat. Res. 183:2 (2015), 196–207.
132. [132] Butz, H., Liko, I., Czirjak, S., Igaz, P., Khan, M.M., Zivkovic, V., et al. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 95:10 (2010), E181–E191.
133. [133] He, J.F., Luo, Y.M., Wan, X.H., Jiang, D., Biogenesis of MiRNA‐195 and its role in biogenesis, the cell cycle, and apoptosis. J. Biochem. Mol. Toxicol. 25:6 (2011), 404–408.
134. [134] Zhang, X., Wan, G., Mlotshwa, S., Vance, V., Berger, F.G., Chen, H., et al. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res. 70:18 (2010), 7176–7186.
135. [135] Xu, J., Li, Y., Wang, F., Wang, X., Cheng, B., Ye, F., et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 32:8 (2013), 976–987.
136. [136] Natarajan, S., Hombach-Klonisch, S., Dröge, P., Klonisch, T., HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia, 15(3), 2013 263-IN13.
137. [137] Wong, P., Iwasaki, M., Somervaille, T.C., Ficara, F., Carico, C., Arnold, C., et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 70:9 (2010), 3833–3842.
138. [138] Karimian, A., Ahmadi, Y., Yousefi, B., Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair 42:7 (2016), 63–71.
139. [139] Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. U. S. A. 106:9 (2009), 3207–3212.
140. [140] Kim, H.H., Kuwano, Y., Srikantan, S., Lee, E.K., Martindale, J.L., Gorospe, M., HuR recruits let-7/RISC to repress c-Myc expression. Genes. Dev. 23:15 (2009), 1743–1748.
141. [141] Li, Y., Challagundla, K.B., Sun, X.-X., Zhang, Q., Dai, M.-S., MicroRNA-130a associates with ribosomal protein L11 to suppress c-Myc expression in response to UV irradiation. Oncotarget, 6(2), 2015, 1101.
142. [142] le Sage, C., Nagel, R., Egan, D.A., Schrier, M., Mesman, E., Mangiola, A., et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26:15 (2007), 3699–3708.
143. [143] Dong, Q., Meng, P., Wang, T., Qin, W., Qin, W., Wang, F., et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One, 5(4), 2010, e10147.
144. [144] Mao, A., Liu, Y., Wang, Y., Zhao, Q., Zhou, X., Sun, C., et al. miR-449a enhances radiosensitivity through modulating pRb/E2F1 in prostate cancer cells. Tumor Biol. 37:4 (2016), 4831–4840.
145. [145] Shi, W., Alajez, N.M., Bastianutto, C., Hui, A.B., Mocanu, J.D., Ito, E., et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int. J. Cancer 126:9 (2010), 2036–2048.
146. [146] Han, Z., Zhang, Y., Xu, Y., Ji, J., Xu, W., Zhao, Y., et al. Cell cycle changes mediated by the p53/miR-34c axis are involved in the malignant transformation of human bronchial epithelial cells by benzo [a] pyrene. Toxicol. Lett. 225:2 (2014), 275–284.
147. [147] Han, L.P., Fu, T., Lin, Y., Miao, J.-L., Jiang, Q.-F., microRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3. Tumor Biol. 37:1 (2016), 291–298.
148. [148] Tian, R.-Q., Wang, X.-H., Hou, L.-J., Jia, W.-H., Yang, Q., Li, Y.-X., et al. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J. Biol. Chem. 286:29 (2011), 25556–25563.
149. [149] Afanasyeva, E.A., Mestdagh, P., Kumps, C., Vandesompele, J., Ehemann, V., Theissen, J., et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ. 18:6 (2011), 974–984.
150. [150] Lin, S.-L., Chang, D.C., Ying, S.-Y., Leu, D., Wu, D.T., MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 70:22 (2010), 9473–9482.
151. [151] Lv, L., Li, Y., Deng, H., Zhang, C., Pu, Y., Qian, L., et al. MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett. 357:1 (2015), 105–113.
152. [152] Liu, G., Sun, Y., Ji, P., Li, X., Cogdell, D., Yang, D., et al. MiR‐506 suppresses proliferation and induces senescence by directly targeting the CDK4/6?FOXM1 axis in ovarian cancer. J. Pathol. 233:3 (2014), 308–318.
153. [153] Huang, Y.-Z., Zhang, J., Shao, H.-Y., Chen, J.-P., Zhao, H.-Y., MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2. Tumor Biol. 36:8 (2015), 6095–6101.
154. [154] Nakazawa, K., Dashzeveg, N., Yoshida, K., Tumor suppressor p53 induces miR‐1915 processing to inhibit Bcl‐2 in the apoptotic response to DNA damage. FEBS J. 281:13 (2014), 2937–2944.
155. [155] Yang, M., Shan, X., Zhou, X., Qiu, T., Zhu, W., Ding, Y., et al. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anti Cancer Agents Med. Chem. (Former. Curr. Med. Chem. AntiCancer Agents) 14:6 (2014), 884–891.
156. [156] Zhang, H.-H., Pang, M., Dong, W., Xin, J.-X., Li, Y.-J., Zhang, Z.-C., et al. miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol. Rep. 31:3 (2014), 1473–1479.
157. [157] Hamada, S., Masamune, A., Miura, S., Satoh, K., Shimosegawa, T., MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell. Signal. 26:2 (2014), 179–185.
158. [158] Lang, A., Grether-Beck, S., Singh, M., Kuck, F., Jakob, S., Kefalas, A., et al. MicroRNA-15b regulates mitochondrial ROS production and the senescence-associated secretory phenotype through sirtuin 4/SIRT4. Aging (Albany NY)., 8(3), 2016, 484.
159. [159] Huang, L.G., Li, J.P., Pang, X.M., Chen, C.Y., Xiang, H.Y., Feng, L.B., et al. MicroRNA‐29c correlates with neuroprotection induced by FNS by targeting both birc2 and bak1 in rat brain after stroke. CNS Neurosci. Ther. 21:6 (2015), 496–503.
160. [160] Li, Y., Deng, H., Lv, L., Zhang, C., Qian, L., Xiao, J., et al. The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Oncotarget, 6(12), 2015, 10195.
161. [161] Zhao, Z., Zhang, L., Yao, Q., Tao, Z., miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells. Cancer Gene Ther. 22:3 (2015), 108–114.
162. [162] Wagner-Ecker, M., Schwager, C., Wirkner, U., Abdollahi, A., Huber, P.E., MicroRNA expression after ionizing radiation in human endothelial cells. Radiat. Oncol., 5(1), 2010, 1.
163. [163] Josson, S., Sung, S.Y., Lao, K., Chung, L.W., Johnstone, P.A., Radiation modulation of microRNA in prostate cancer cell lines. Prostate 68:15 (2008), 1599–1606.
164. [164] Majidinia, M., Yousefi, B., Long non-coding RNAs in cancer drug resistance development. DNA Repair 45:9 (2016), 25–33.
165. [165] Choi, W.-Y., Giraldez, A.J., Schier, A.F., Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 318:5848 (2007), 271–274.
166. [166] Esquela-Kerscher, A., Trang, P., Wiggins, J.F., Patrawala, L., Cheng, A., Ford, L., et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. ABBV Cell Cycle 7:6 (2008), 759–764.
167. [167] Kota, J., Chivukula, R.R., O'Donnell, K.A., Wentzel, E.A., Montgomery, C.L., Hwang, H.-W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:6 (2009), 1005–1017.
168. [168] Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:7 (2004), 927–939.
169. [169] Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E.G., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28:4 (2010), 341–347.
170. [170] Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:34 (2005), 12177–12182.
171. [171] Wang, Q., Zhong, M., Liu, W., Li, J., Huang, J., Zheng, L., Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp. Lung Res. 37:7 (2011), 427–434.
172. [172] Bisso, A., Faleschini, M., Zampa, F., Capaci, V., De Santa, J., Santarpia, L., et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. ABBV Cell Cycle 12:11 (2013), 1679–1687.
173. [173] Zhu, D.-X., Zhu, W., Fang, C., Fan, L., Zou, Z.-J., Wang, Y.-H., et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 33:7 (2012), 1294–1301.
174. [174] Gasparini, P., Cascione, L., Fassan, M., Lovat, F., Guler, G., Balci, S., et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 5:5 (2014), 1174–1184.
175. [175] Gasparini, P., Lovat, F., Fassan, M., Casadei, L., Cascione, L., Jacob, N.K., et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc. Natl. Acad. Sci. U. S. A. 111:12 (2014), 4536–4541.
176. [176] Cascione, L., Gasparini, P., Lovat, F., Carasi, S., Pulvirenti, A., Ferro, A., et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One, 8(2), 2013, e55910.
177. [177] Neijenhuis, S., Bajrami, I., Miller, R., Lord, C.J., Ashworth, A., Identification of miRNA modulators to PARP inhibitor response. DNA Repair 12:6 (2013), 394–402.
178. [178] Pogribny, I.P., Filkowski, J.N., Tryndyak, V.P., Golubov, A., Shpyleva, S.I., Kovalchuk, O., Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin. Int. J. Cancer 127:8 (2010), 1785–1794.
179. [179] Doles, J., Oliver, T.G., Cameron, E.R., Hsu, G., Jacks, T., Walker, G.C., et al. Suppression of Rev3, the catalytic subunit of Polξ, sensitizes drug-resistant lung tumors to chemotherapy. Proc. Natl. Acad. Sci. U. S. A. 107:48 (2010), 20786–20791.
180. [180] Zhou, M., Liu, Z., Zhao, Y., Ding, Y., Liu, H., Xi, Y., et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J. Biol. Chem. 285:28 (2010), 21496–21507.
181. [181] Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., Ito, M., MiR‐34a attenuates paclitaxel‐resistance of hormone‐refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70:14 (2010), 1501–1512.
182. [182] Kastl, L., Brown, I., Schofield, A., miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res. Treat. 131:2 (2012), 445–454.
183. [183] Ren, Y., Zhou, X., Mei, M., Yuan, X.-B., Han, L., Wang, G.-X., et al. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer, 10(1), 2010, 27.
184. [184] Zhang, Y.-X., Yue, Z., Wang, P.-Y., Li, Y.-J., Xin, J.-X., Pang, M., et al. Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth. Biomed. Pharmacother. 67:2 (2013), 97–102.
185. [185] Giovannetti, E., Funel, N., Peters, G.J., Del Chiaro, M., Erozenci, L.A., Vasile, E., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70:11 (2010), 4528–4538.
186. [186] Ferracin, M., Zagatti, B., Rizzotto, L., Cavazzini, F., Veronese, A., Ciccone, M., et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol. Cancer, 9(1), 2010, 1.
187. [187] van Jaarsveld, M.T., Wouters, M.D., Boersma, A.W., Smid, M., van I.Jcken, W.F., Mathijssen, R.H., et al. DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. Mol. Oncol. 8:3 (2014), 458–468.
188. [188] Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., Tryndyak, V.P., Vasyl'F, C., et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7:7 (2008), 2152–2159.
189. [189] Zhou, Y., Wan, G., Spizzo, R., Ivan, C., Mathur, R., Hu, X., et al. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol. Oncol. 8:1 (2014), 83–92.
190. [190] Sugio, A., Iwasaki, M., Habata, S., Mariya, T., Suzuki, M., Osogami, H., et al. BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer. Gynecol. Oncol. 134:3 (2014), 615–623.
191. [191] Li, J., Wang, Y., Song, Y., Fu, Z., Yu, W., miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol. Cancer, 13(1), 2014, 1.
192. [192] Deng, H., Lv, L., Li, Y., Zhang, C., Meng, F., Pu, Y., et al. The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 1852:3 (2015), 520–528.
193. [193] Wan, L.-Y., Deng, J., Xiang, X.-J., Zhang, L., Yu, F., Chen, J., et al. miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem. Biophys. Res. Commun. 457:2 (2015), 125–132.
194. [194] Samuel, P., Pink, R.C., Caley, D.P., Currie, J.M.S., Brooks, S.A., Carter, D.R.F., Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells. Tumor Biol. 37:2 (2016), 2565–2573.